Innovating Works

LUMICKS

Financiado
z Movi cell screening and sorting platform
Cell immunotherapy is a breakthrough treatment that uses immune cells to directly attack tumours. It is considered the most exciting development in cancer treatment in years. When it works, patients with life-threatening cancers l... Cell immunotherapy is a breakthrough treatment that uses immune cells to directly attack tumours. It is considered the most exciting development in cancer treatment in years. When it works, patients with life-threatening cancers live far longer or may even be cured. But so far, immunotherapy only works for few types of cancer and few patients, and finding the most effective immune cells is still an immense challenge. LUMICKS is developing z-Movi, the first high-throughput platform that screens and sorts immune cells based on their functionality using non-invasive techniques. z-Movi is a unique and powerful solution that now allows researchers to look at thousands of immune cells and find the right ones within a couple of minutes – a process that would take months with standard technologies. Therefore, z-Movi is the perfect R&D tool to help and speed up the process of bringing new immunotherapy treatments to market. z-Movi is expected to disrupt the immunotherapy market, which is mostly driven by innovation and is expected to reach €100B by 2021. LUMICKS started by teaming-up with immunotherapy leaders such as the Dutch Cancer Institute and Institut Pasteur to develop z-Movi. The first developed z-Movi was already introduced to early adopters. After completing optimisation, a new generation z-Movi will target the immunology research institutes, biotech and pharma markets. Users from those segments have already demonstrated concrete interest in our solution, or are in the process of acquisition. The incremental z-Movi revenue stream from this EIC Accelerator project will be around €20M by 2022 and the net profit margin will double. LUMICKS’ post-EIC ultimate goal is to go beyond the ver más
30/09/2022
LUMICKS CA BV
3M€
Duración del proyecto: 24 meses Fecha Inicio: 2020-09-16
Fecha Fin: 2022-09-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2022-09-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020: SME instrument
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 3M€
Líder del proyecto
LUMICKS CA BV No se ha especificado una descripción o un objeto social para esta compañía.